Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease

NCT05422092 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus With Complication

Interventions

DRUG: Canagliflozin
DRUG: Pioglitazone

Sponsor

First Affiliated Hospital Xi'an Jiaotong University